Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab

<b>High clinical suspicion</b> recognition of early signs of dermolysis is essential in managing severe cutaneous toxicity associated with enfortumab vedotin.<b>A multidisciplinary approach</b> the management of Stevens-Johnson syndrome/toxic epidermal necrolysis should involve a multidisciplinary team, especially in patients with complex comorbidities.<b>Pharmacovigilance</b> continuous monitoring and prompt reporting of adverse events to health authorities are vital for improving patient safety and therapeutic outcomes.